Aptevo Therapeutics Inc.
APVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671584
No open-market purchases or sales by Aptevo Therapeutics Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $224.3K in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding Aptevo Therapeutics Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 27 | 24 | −3 |
| Shares | 963.4K | 891.6K | −71.8K (−7.4%) |
| Value | $2.27M | $1.82M | −$455.6K (−20.1%) |
New holders (3)
Institutions that held Aptevo Therapeutics Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Royal Bank of Canada | 1,700 | $3.00K | 0.00% |
| Advisor Group Holdings, Inc. | 30 | $61 | 0.00% |
| Allworth Financial LP | 17 | $35 | 0.00% |
Sold out (6)
Institutions that held Aptevo Therapeutics Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Citadel Advisors LLC | 42,071 | $97.6K |
| Two Sigma Securities, LLC | 14,877 | $34.5K |
| UBS Group AG | 1,430 | $3.32K |
| Money Concepts Capital Corp | 7 | $16 |
| FMR LLC | 3 | $8 |
| Tower Research Capital LLC (TRC) | 113 | $0 |